Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06600022

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB41 in Patients with Advanced Malignant Solid Tumours

Sponsor: Sinocelltech Ltd.

Conditions Advanced Malignant Solid Tumours

Interventions SCTB41

Updated 2 times since 2024 Last updated: Jan 14, 2025 Started: Oct 10, 2024 Primary completion: Apr 30, 2027 Completion: Apr 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Malignant Solid Tumours, this trial is actively recruiting participants. The trial is conducted by Sinocelltech Ltd. and has accumulated 2 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Feb 2025 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinocelltech Ltd.

Data source: Sinocelltech Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China